Business
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021
KZR-616 demonstrates improvement across all exploratory efficacy measures and is observed to be well-tolerated up to 75 mg subcutaneously once weekly for 13
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":"\n\nKZR-616 demonstrates improvement across all exploratory efficacy measures and is observed to be well-tolerated up to 75 mg subcutaneously once weekly for 13 weeks.\n\n\n\nThe MISSION Phase 1b data support the development of KZR-616 in multiple immune-mediated diseases.\n\n\n\nConference call and webcast to be held at 4:30pm ET.\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nKezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported results from the completed Phase 1b dose escalation portion of its MISSION study, evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in systemic lupus erythematosus (SLE) patients with and without nephritis. The data are being presented by Richard Furie, M.D., Chief of Division of Rheumatology at Northwell Health in New York, in a poster session at EULAR, the Annual European Congress of Rheumatology, being held virtually from June 2 to 5, 2021. The poster can be found on Kezar’s website under the “Our Science” section.\n\n“MISSION Phase 1b was planned as a dose-finding study but provided us with a wealth of information beyond dosing. The safety and tolerability profile seen with KZR-616 appears favorable for a treatment that would be use in chronic diseases,” said Noreen R. Henig, M.D., Kezar’s Chief Medical Officer. “Importantly, the observed improvement across multiple exploratory efficacy measures and key biomarkers, including a highly specific marker of kidney inflammation, increases our conviction that KZR-616 has the potential to disrupt the treatment paradigm for immune-mediated diseases such as SLE and LN.”\n\nThe Phase 1b dose escalation portion of MISSION (NCT03393013) evaluated doses of 45 mg to 75 mg of KZR-616 administered subcutaneously once weekly in 47 patients with SLE, including 2 patients with active proliferative lupus nephritis (LN). Six cohorts were completed in which patients received 13 weekly doses of KZR-616 and were followed for an additional 12 weeks. 35 of 47 patients completed the study. Safety, tolerability, and early efficacy has been previously reported from early cohorts. The presentation at EULAR 2021 represents the full data set.\n\nHighlights from the poster presentation of the MISSION Phase 1b are su...